RYHTY:OTO-Ryman Healthcare Ltd ADR Repstg 5 Shs (USD)

COMMON STOCK | Medical Care Facilities | OTC Pink

Last Closing

USD 15

Change

0.00 (0.00)%

Market Cap

USD 3.07B

Volume

2.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ryman Healthcare Ltd is a profit-oriented entity that develops, owns and operates integrated retirement villages, resthomes and hospitals for the elderly within New Zealand and Australia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
FSNUF Fresenius SE & Co. KGaA

N/A

USD 20.89B
BDUUY Bangkok Dusit Medical Services..

N/A

USD 13.86B
FMCQF Fresenius Medical Care AG & Co..

N/A

USD 12.25B
RMYHY Ramsay Health Care Ltd ADR

N/A

USD 6.16B
HYHHF Hygeia Healthcare Holdings Co ..

N/A

USD 3.14B
AEVIF Aevis Victoria SA

N/A

USD 1.69B
DNTCF dentalcorp Holdings Ltd.

+0.14 (+2.35%)

USD 1.16B
RHKJF RHÖN-KLINIKUM Aktiengesellsch..

N/A

USD 0.82B
PFSMF Perfect Medical Health Managem..

N/A

USD 0.70B
EXETF Extendicare Inc

-0.10 (-1.37%)

USD 0.56B

ETFs Containing RYHTY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.43% 48% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.43% 45% F 43% F
Trailing 12 Months  
Capital Gain -22.68% 40% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.68% 38% F 38% F
Trailing 5 Years  
Capital Gain -65.60% 45% F 32% F
Dividend Return 5.08% 27% F 19% F
Total Return -60.53% 50% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain -18.97% 30% F 14% F
Dividend Return -17.73% 30% F 15% F
Total Return 1.25% 29% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 29.87% 76% C+ 72% C
Risk Adjusted Return -59.35% 27% F 12% F
Market Capitalization 3.07B 90% A- 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector